** Shares of Relay Therapeutics RLAY.O rise 7.5% to $4.76 premarket
** Co says its lead drug candidate to treat a type of locally advanced breast cancer helped patients live for about 11.4 months on average without the disease getting worse
** The drug, RLY-2608, is being tested in combination with hormone therapy
** RLAY plans to start a pivotal study testing the combination next year
** The combination was generally well tolerated in the 118 patients treated -RLAY
** Two patients discontinued treatment due to treatment-related side-effects such as nausea and loss of appetite
** Up to last close, stock down ~60% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。